Identification of Aryl Polyamines Derivatives as Anti-Trypanosoma cruzi Agents Targeting Iron Superoxide Dismutase
Metadata
Show full item recordAuthor
Martín Escolano, Rubén; Molina Carreño, Daniel; Rosales Lombardo, María José; Marín Sánchez, ClotildeEditorial
MDPI
Materia
Chagas disease Chemotherapy Drug discovery Aryl polyamines Trypanosoma cruzi
Date
2022-12-31Referencia bibliográfica
Martín-Escolano, R... [et al.]. Identification of Aryl Polyamines Derivatives as Anti-Trypanosoma cruzi Agents Targeting Iron Superoxide Dismutase. Pharmaceutics 2023, 15, 140. [https://doi.org/10.3390/pharmaceutics15010140]
Sponsorship
Ministerio de Economia, Industria y Competitividad (CONSOLIDER CSD2010–00065 and CTQ2017–90852-REDC); MINECO and FEDER funds from the EU (Projects PID2019-110751RB-I00, RED2018-102331-T and Unidad de Excelencia María de Maeztu CEX2019-000919-M); Alfonso Martín Escudero FoundationAbstract
Chagas disease (CD) is a tropical and potentially fatal infection caused by Trypanosoma cruzi.
Although CD was limited to Latin America as a silent disease, CD has become widespread as a result
of globalization. Currently, 6–8 million people are infected worldwide, and no effective treatment is
available. Here, we identify new effective agents against T. cruzi. In short, 16 aryl polyamines were
screened in vitro against different T. cruzi strains, and lead compounds were evaluated in vivo after
oral administration in both the acute and chronic infections. The mode of action was also evaluated
at the energetic level, and its high activity profile could be ascribed to a mitochondria-dependent
bioenergetic collapse and redox stress by inhibition of the Fe-SOD enzyme. We present compound
15 as a potential compound that provides a step forward for the development of new agents to
combat CD.